SCHEMBL871824

SCHEMBL871824

O=C1C=C(I)C(=O)C(Cl)=C1O

nearest known ligand 0.32

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
XIAP P98170 1/20 0.32
MEN1 O00255 1/20 0.30
USP2 O75604 1/20 0.30
ALDH1A1 P00352 1/20 0.30
LMNA P02545 1/20 0.30
TP53 P04637 1/20 0.30
GLA P06280 1/20 0.30
CYP3A4 P08684 1/20 0.30
MAPT P10636 1/20 0.30
THRB P10828 1/20 0.30
HPGD P15428 1/20 0.30
ALOX15 P16050 1/20 0.30
ALOX12 P18054 1/20 0.30
MAPK1 P28482 1/20 0.30
BRCA1 P38398 1/20 0.30
BLM P54132 1/20 0.30
KMT2A Q03164 1/20 0.30
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27615467 0.76 XIAP (0.48) XIAPMEN1USP2ALDH1A1TP53
SCHEMBL2536906 0.71 P2RX7 (0.35) XIAPMEN1ALDH1A1LMNAMAPT
SCHEMBL223460 0.65 ALDH1A1 (0.47) MEN1USP2ALDH1A1LMNATP53
SCHEMBL871823 0.64 XIAP (0.36) XIAPMEN1USP2ALDH1A1LMNA
SCHEMBL27797012 0.63 KDM4E (0.44) MEN1ALDH1A1LMNATP53CYP3A4
SCHEMBL3320693 0.63 KDM4E (0.44) MEN1ALDH1A1LMNATP53CYP3A4
Water SCHEMBL9062657 0.63 KDM4E (0.50) MEN1ALDH1A1LMNATP53CYP3A4
SCHEMBL5081850 0.63 KDM4E (0.44) MEN1ALDH1A1LMNATP53CYP3A4
SCHEMBL5081810 0.63 KDM4E (0.44) MEN1ALDH1A1LMNATP53CYP3A4
SCHEMBL929847 0.63 KDM4E (0.44) MEN1ALDH1A1LMNATP53CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1928415-A2 TOPICAL DELIVERY WITH A CARRIER FLUID Collegium Pharmaceutical, Inc. (US) 2008-06-11 EP claimed
WO-2007022090-A2 TOPICAL DELIVERY WITH A CARRIER FLUID COLLEGIUM PHARMACEUTICAL, INC. (US) 2007-02-22 WO claimed
US-20070036731-A1 Topical Delivery with a Carrier Fluid COLLEGIUM PHARMACEUTICAL, INC. 2007-02-15 US claimed
EP-3226977-B1 GLASS COMPOSITES FOR TISSUE AUGMENTATION, BIOMEDICAL AND COSMETIC APPLICATIONS UNIV RES INST INC AUGUSTA (US) 2021-06-23 EP disclosed
US-20190117828-A1 Glass Composites for Tissue Augmentation, Biomedical and Cosmetic Applications AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. 2019-04-25 US disclosed
US-10201633-B2 Glass composites for tissue augmentation, biomedical and cosmetic applications AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. (US) 2019-02-12 US disclosed
US-9920058-B2 Molecules with potent DHFR binding affinity and antibacterial activity GEORGIA TECH RESEARCH CORPORATION (US) 2018-03-20 US disclosed
US-20170354755-A1 Glass Composites for Tissue Augmentation, Biomedical and Cosmetic Applications AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. 2017-12-14 US disclosed
EP-3226977-A2 GLASS COMPOSITES FOR TISSUE AUGMENTATION, BIOMEDICAL AND COSMETIC APPLICATIONS Augusta University Research Institute, Inc. (US) 2017-10-11 EP disclosed
CN-102949387-B For treating compositionss and the method for herpes simplex virus 奥古斯塔大学研究所公司 2017-03-01 CN disclosed
US-9446017-B2 Compositions and methods for treating herpes simplex virus AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. (US) 2016-09-20 US disclosed
EP-1928415-A2 TOPICAL DELIVERY WITH A CARRIER FLUID Collegium Pharmaceutical, Inc. (US) 2008-06-11 EP disclosed
EP-1922067-A1 MODIFIED GREEN TEA POLYPHENOL FORMULATIONS Medical College Of Georgia Research Institute (US) 2008-05-21 EP disclosed
WO-2007021789-A1 MODIFIED GREEN TEA POLYPHENOL FORMULATIONS MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE (US) 2007-02-22 WO disclosed
WO-2007022090-A2 TOPICAL DELIVERY WITH A CARRIER FLUID COLLEGIUM PHARMACEUTICAL, INC. (US) 2007-02-22 WO disclosed
US-20070036731-A1 Topical Delivery with a Carrier Fluid COLLEGIUM PHARMACEUTICAL, INC. 2007-02-15 US disclosed
WO-2006138056-A1 PHARMACEUTICAL COMPOSITION COMPRISING A MAHONIA AQUIFOLIUM EXTRACT FOR THE TREATMENT OF PSORIASIS APOLLO PHARMACEUTICAL, INC. (US) 2006-12-28 WO disclosed
US-20060286054-A1 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PSORIASIS APOLLO PHARMACEUTICAL, INC. 2006-12-21 US disclosed
WO-2005115336-A2 SPRAYABLE FORMULATIONS FOR THE TREATMENT OF ACUTE INFLAMMATORY SKIN CONDITIONS COLLEGIUM PHARMACEUTICAL, INC. (US) 2005-12-08 WO disclosed
US-20050255048-A1 Sprayable formulations for the treatment of acute inflammatory skin conditions COLLEGIUM PHARMACEUTICAL, INC. 2005-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060286054-A1 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PSORIASIS VDR, CYP24A1, CYP2R1 XIAP 3464/4885MEN1 3019/4885USP2 4703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.